Changeflow GovPing Healthcare & Life Sciences FDA CDER Final Response Letter to AdventaPharma...
Routine Enforcement Added Final

FDA CDER Final Response Letter to AdventaPharma DWC-LLC

Email

Summary

The FDA's Center for Drug Evaluation and Research (CDER) has issued a final response letter to AdventaPharma DWC-LLC. This document is part of the ongoing regulatory process for drug applications and does not appear to contain new compliance obligations.

Published by FDA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The FDA's Center for Drug Evaluation and Research (CDER) has issued a final response letter to AdventaPharma DWC-LLC, identified by docket number FDA-2025-P-5582-0003. This communication is part of the standard regulatory review process for pharmaceutical products and does not introduce new compliance requirements or penalties for other entities.

As this is a specific response to a company's submission, there are no immediate required actions for other regulated entities. Compliance officers should note this as part of the FDA's ongoing regulatory activities in the pharmaceutical sector. No compliance deadline or penalty information is applicable to this specific document.

Archived snapshot

Mar 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

There are no documents available to view or download

Attachments 1

Final Response Letter from FDA CDER to AdventaPharma DWC-LLC

More Information
- Author(s) CDER
Download

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Enforcement
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
FDA-2025-P-5582-0003
Docket
FDA-2025-P-5582-0003

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Approval
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Compliance
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Drug Approval Regulatory Compliance

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!